1 – 10 of 196
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Nine areas with outstanding challenges for hemophilia B research
- Contribution to journal › Scientific review
-
Mark
Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B : Results From a Phase 3 Study
- Contribution to journal › Letter
-
Mark
florio HAEMO—A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia
- Contribution to journal › Article
-
Mark
Noncarrier mothers of hemophilia A patients with Intron 22 inversions often have other rearrangements
- Contribution to journal › Article
- 2025
-
Mark
Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries–Comparisons to Matched Controls
- Contribution to journal › Article
-
Mark
A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis
- Contribution to journal › Article
-
Mark
Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab : Results From the Phase IV HemiNorth 2 Study
- Contribution to journal › Article
-
Mark
Evaluation of kidney function and damage in patients with hemophilia B—insights from the B-Natural study
- Contribution to journal › Article
-
Mark
Haemophilia B : an illustrative review of current challenges and opportunities
- Contribution to journal › Article
-
Mark
Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy
- Contribution to journal › Article
